Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    logos
    2 October 2024

    ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

    License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services Dublin, Ireland, and Montreal, Canada, 01 October 2024: ERS Genomics Limited, the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Can...

    Cyto-Mine Chroma
    1 October 2024

    Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development

    Next generation of industry-leading Cyto-Mine platform will offer new capabilities to optimize single-cell analysis workflow efficiency Opens up new, multiplexed assays and applications for antibody discovery and cell line development, and allows entry into new markets such as cell ...

    Challenges and Advances in Asthma Treatment
    3 October 2024

    Challenges and advances in asthma treatment

    An In-depth Conversation with Dr. Andrew Potter of Whaddon Medical Centre Asthma remains a persistent challenge in healthcare, affecting both adults and children alike. In a recent podcast, Dr. Andrew Potter, GP lead at Wadden Medical Center in Milton Keynes, shared his valuable insigh...

    Know your customer: Strategic considerations for AI-powered provider segmentation
    1 October 2024

    Know your customer: strategic considerations for AI-powered provider segmentation

    Published in Life Science Leader, CRA’s Robert Broadnax, Eddie Li and Brian Carpenter co-authored an article “Know Your Customer: Strategic Considerations for AI-Powered Provider Segmentation,” focused on the strategic considerations for drug manufacturers in developing an AI-powered pr...

    Owlstone medical logo
    30 September 2024

    Owlstone Medical partners with the FDA to advance the identification of volatile organic compounds in breath and expand its Breath Biopsy VOC Atlas.

    Collaboration will develop analytical methods to improve the identification of specific chemicals in complex gaseous mixtures Owlstone will use the developed methods and techniques to enhance its work in the field of breath-based biomarkers of disease Project will also help extend ...

    Fujifilm logo
    27 September 2024

    FUJIFILM Irvine Scientific Adds Key Products To Its Life Sciences Portfolio From FUJIFILM Wako Chemicals U.S.A.

    Additional products in lab automation, lab chemicals and LAL expand complete solutions available directly from FUJIFILM Irvine Scientific to customers in US and Europe Sales agreement aligns business and commercial operations to maximize customer benefit SANTA ANA, Calif: FUJIFILM...

    transforming healthcare
    26 September 2024

    Transforming healthcare: the power of purpose-led partnerships

    In this episode, ⁠Dr Bipin Patel⁠ sits down with ⁠Samuel Hollis⁠, Country President and Managing Director at ⁠Novartis⁠ to explore the key elements of forming impactful healthcare partnerships. ...

    Dr John Ford, CEO, Enterprise Therapeutics
    26 September 2024

    Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001

    ETD001 is a novel, first in class blocker of the epithelial sodium channel (ENaC) aimed at treating people with cystic fibrosis without current effective therapies ETD001 commenced Phase 2 clinical trials in July 2024, expected to complete in 2025 Brighton, UK: Enterprise Therapeu...

    Dengue fever
    25 September 2024

    Takeda’s Qdenga® - more campaigns needed before single-dose products arrive

    This month VacZine Analytics, a specialist in infectious diseases and vaccines commercial analysis publishes a brand-new global analysis of the dengue endemic vaccines market. ...

    logo
    24 September 2024

    Steritas’ Pediatric Glucocorticoid Toxicity Index used by Alder Hey and Liverpool Trials Centre to assess steroid toxicity in children with juvenile idiopathic arthritis

    Study will allow researchers to assess the outcomes of intravenous and oral glucocorticoid protocols in children ...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 117
    • Page 118
    • Current page 119
    • Page 120
    • Page 121
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS